Free Trial

CNS Pharmaceuticals Q3 2023 Earnings Report

CNS Pharmaceuticals logo
$1.10 -0.03 (-2.65%)
As of 04:00 PM Eastern

CNS Pharmaceuticals EPS Results

Actual EPS
-$2,700.00
Consensus EPS
-$4,325.00
Beat/Miss
Beat by +$1,625.00
One Year Ago EPS
N/A

CNS Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

CNS Pharmaceuticals Announcement Details

Quarter
Q3 2023
Time
After Market Closes

Conference Call Resources

Remove Ads

CNS Pharmaceuticals Earnings Headlines

CNS Pharmaceuticals sees cash runway into 1Q26
This almost killed Elon Musk (chilling details emerge)
Elon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a terrifying supercar crash with billionaire Peter Thiel, then from a deadly strain of malaria—Elon Musk emerged with a stark warning for Americans about looming financial dangers. Discover the little-known Trump IRS loophole that thousands are now using to safeguard their retirement from inflation and market turmoil—before it's too late.
CNS Pharmaceuticals announces primary analysis of berubicin in GBM
See More CNS Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like CNS Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CNS Pharmaceuticals and other key companies, straight to your email.

About CNS Pharmaceuticals

CNS Pharmaceuticals (NASDAQ:CNSP), a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.

View CNS Pharmaceuticals Profile

More Earnings Resources from MarketBeat